$2.02
+0.01 (+0.50%)
Open$2.02
Previous Close$2.01
Day High$2.04
Day Low$1.97
52W High$5.84
52W Low$0.97
Volume—
Avg Volume78.4K
Market Cap6.89M
P/E Ratio—
EPS$-82,447.68
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+2,038.6% upside
Current
$2.02
$2.02
Target
$43.20
$43.20
$28.55
$43.20 avg
$44.32
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.69M | 1.69M | 1.36M |
| Net Income | 118.4K | 113.8K | 71.1K |
| Profit Margin | 7.0% | 6.8% | 5.2% |
| EBITDA | 180.1K | 185.2K | 152.7K |
| Free Cash Flow | 113.7K | 84.7K | 88.4K |
| Rev Growth | -7.6% | +15.2% | +21.3% |
| Debt/Equity | 0.66 | 0.76 | 0.92 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |